CMS(00867)

8.430-0.050-0.59%

CommunityCommunity
NewsNews
ProfileProfile
AnnouncementsAnnouncements

- China Medical System's Cardiac Myosin Inhibitor Gets China's Clinical Trial Approval; Shares Up 3%
  MT Newswires Live · 03-13 07:35
  China Medical System's Cardiac Myosin Inhibitor Gets China's Clinical Trial Approval; Shares Up 3%
- BUZZ-China Medical System rises on drug clinical trials approval
  Reuters · 03-13 04:21
  BUZZ-China Medical System rises on drug clinical trials approval
- China Medical System （867.HK） Is Included in the S&P Global Sustainability Yearbook 2025
  THOMSON REUTERS · 02-14
  China Medical System （867.HK） Is Included in the S&P Global Sustainability Yearbook 2025
- China Medical System Holdings Limited (HKG:867) insiders have significant skin in the game with 52% ownership
  Simply Wall St. · 02-03
  China Medical System Holdings Limited (HKG:867) insiders have significant skin in the game with 52% ownership
- BRIEF-China Medical System Announces Agreement For Antibody Injection
  Reuters · 01-24
  BRIEF-China Medical System Announces Agreement For Antibody Injection
- China Medical System（00867）Obtained Class 1 Innovative Drug Long-acting Anti-IL-4Rα Monoclonal Antibody MG-K10
  GlobeNewswire · 01-24
  China Medical System（00867）Obtained Class 1 Innovative Drug Long-acting Anti-IL-4Rα Monoclonal Antibody MG-K10
- China Medical System - Agreement for Class 1 Innovative Drug Mg-K10 Humanized Monoclonal Antibody Injection
  THOMSON REUTERS · 01-24
  China Medical System - Agreement for Class 1 Innovative Drug Mg-K10 Humanized Monoclonal Antibody Injection
- China Medical System Signs License Deal with Alpha Cognition for Alzheimer's Drug
  MT Newswires Live · 01-09
  China Medical System Signs License Deal with Alpha Cognition for Alzheimer's Drug
- BRIEF-China Medical System Announces License, Collaboration And Distribution Agreement For Zunveyl
  Reuters · 01-08
  BRIEF-China Medical System Announces License, Collaboration And Distribution Agreement For Zunveyl
- China Medical System （00867）Obtained New Drug ZUNVEYL for the Treatment of Mild-to-Moderate Dementia of the Alzheimer’s Type
  GlobeNewswire · 01-08
  China Medical System （00867）Obtained New Drug ZUNVEYL for the Treatment of Mild-to-Moderate Dementia of the Alzheimer’s Type
- China Medical System - Under Deal, Group to Have Exclusive Right to Develop, Others, Product in Asia (Excluding Japan), Australia and New Zealand
  THOMSON REUTERS · 01-08
  China Medical System - Under Deal, Group to Have Exclusive Right to Develop, Others, Product in Asia (Excluding Japan), Australia and New Zealand
- China Medical System - Agreement for Improved New Drug Zunveyl for Treatment of Mild-to-Moderate Dementia of Alzheimer's Type
  THOMSON REUTERS · 01-08
  China Medical System - Agreement for Improved New Drug Zunveyl for Treatment of Mild-to-Moderate Dementia of Alzheimer's Type
- China Medical System - License, Collaboration and Distribution Agreement With Alpha Cognition
  THOMSON REUTERS · 01-08
  China Medical System - License, Collaboration and Distribution Agreement With Alpha Cognition
- Investors Continue Waiting On Sidelines For China Medical System Holdings Limited (HKG:867)
  Simply Wall St. · 01-07
  Investors Continue Waiting On Sidelines For China Medical System Holdings Limited (HKG:867)
- Declining Stock and Decent Financials: Is The Market Wrong About China Medical System Holdings Limited (HKG:867)?
  Simply Wall St. · 2024-12-17
  Declining Stock and Decent Financials: Is The Market Wrong About China Medical System Holdings Limited (HKG:867)?
- China Medical System Gets Commercialization Rights for Anti-Gout Drug
  MT Newswires Live · 2024-12-03
  China Medical System Gets Commercialization Rights for Anti-Gout Drug
- BRIEF-China Medical System Says Unit Entered Into Exclusive Commercialization Agreement
  Reuters · 2024-12-02
  BRIEF-China Medical System Says Unit Entered Into Exclusive Commercialization Agreement
- China Medical System - Deal for Commercialization of Class 1 Innovative Drug Abp-671 for Treatment of Gout & Hyperuricemia
  THOMSON REUTERS · 2024-12-02
  China Medical System - Deal for Commercialization of Class 1 Innovative Drug Abp-671 for Treatment of Gout & Hyperuricemia
- China Medical System Holdings - Unit Entered Into Exclusive Commercialization Agreemen With Atom Therapeutics
  THOMSON REUTERS · 2024-12-02
  China Medical System Holdings - Unit Entered Into Exclusive Commercialization Agreemen With Atom Therapeutics
- China Medical System's CMS-D005 Approved for Clinical Trial by Chinese Regulator
  MT Newswires Live · 2024-11-28
  China Medical System's CMS-D005 Approved for Clinical Trial by Chinese Regulator
Company Profile
Company Name
CMS
Market
SEHK
Establishment Date
1995
Employees
5781
Office Location
Island Place Tower,Unit 2106,21st Floor,510 King’s Road,North Point,Hong Kong
Website
http://www.cms.net.cn
Zip Code
- -
Phone
852 2369 7678
Fax
852 2389 1320
Introduction
China Medical System Holdings Limited is a Hong Kong-based investment holding company principally engaged in the manufacture, marketing, promotion and sales of pharmaceutical products. Its main products under direct network include Deanxit, Ursofalk, XinHuoSu, Salofalk, Bioflor and Augentropfen Stulln Mono Eye-drops, among others. Its products under the agency promotion network include ShaDuoLiKa, YiNuoShu and XiDaKang, among others. The products of the Company are used in the treatment of gastropathy, cardiopathy, traumatic infection, hepatopathy and eye diseases, among others.
Industry
Pharmaceuticals
IPO Information
Listing Date
- -
Issue Price
- -